{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:41:50Z","timestamp":1789180910624,"version":"build-2803163510"},"reference-count":57,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Phase 3 trials evaluating inhibitors of coagulation factor XI (FXI) and\/or its activated form (FXIa) as novel anticoagulant drugs are ongoing. These agents include parenteral monoclonal antibody (abelacimab) and oral small molecules (milvexian, asundexian). We investigated the extent to which standard and specialized coagulation assays are affected by FXI(a) inhibitors in a multicenter study involving 23 laboratories. FXI(a) inhibitors were spiked into pooled normal plasma at concentrations covering those observed in phase 2\/3 clinical trials: 50 to 2000 ng\/mL for milvexian and asundexian, and 1 to 30 \u03bcg\/mL for abelacimab. Actual plasma concentrations were measured by high-performance liquid chromatography\u2013tandem mass spectrometry. Assays were performed blindly using 5 to 11 different combinations of reagent\/analyzer depending on the assay. Prothrombin time, Clauss fibrinogen, and clotting activity of FII, FV, FVII, and FX were not affected in a clinically relevant manner. Activated partial thromboplastin time (aPTT) was prolonged in a concentration-dependent manner, with milvexian having the greatest impact followed by abelacimab and asundexian. Clotting activity of FVIII, FIX, FXI, and FXII was underestimated. Such interference was prevented by high plasma dilution (up to 1:160) before the test, except for abelacimab: FXI clotting activity remained decreased, even at low concentration (2.5 \u03bcg\/mL). FXI(a) inhibitors did not affect lupus anticoagulant (LA) testing using dilute Russell viper venom time but may lead to false-negative result with LA-sensitive aPTT reagents. Protein C anticoagulant activity was overestimated, whereas no impact on protein S anticoagulant activity was observed. This study provides a comprehensive laboratory framework for interpreting clotting assays in future patients receiving FXI(a) inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020472","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:59:47Z","timestamp":1779879587000},"page":"5762-5774","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6310-8996","authenticated-orcid":false,"given":"Laurie","family":"Goubeau","sequence":"first","affiliation":[{"name":"1Lariboisi\u00e8re University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (Nord), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8382-1493","authenticated-orcid":false,"given":"Emmanuel","family":"Curis","sequence":"additional","affiliation":[{"name":"1Lariboisi\u00e8re University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (Nord), Paris, France"},{"name":"2Lariboisi\u00e8re University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (Nord), Paris Cit\u00e9 university, UR 7537 BioSTM (Biostatistics), Facult\u00e9 de Pharmacie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7134-0713","authenticated-orcid":false,"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[{"name":"3Laboratory of Pharmacologie and Toxicologie, H\u00f4pital Nord, University Hospital Center of Saint-Etienne, France"},{"name":"4INSERM, UMR 1059, Dysfonction Vasculaire et de l\u2032H\u00e9mostase, Lyon University, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-9005","authenticated-orcid":false,"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[{"name":"5Laboratory of Hematology, Pontchaillou University Hospital of Rennes, Rennes University, Rennes, France"},{"name":"6Rennes University, INSERM, EHESP, IRSET UMR-S-1085, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4893-3195","authenticated-orcid":false,"given":"Sophie","family":"Hodin","sequence":"additional","affiliation":[{"name":"4INSERM, UMR 1059, Dysfonction Vasculaire et de l\u2032H\u00e9mostase, Lyon University, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7165-3752","authenticated-orcid":false,"given":"Adrien","family":"Genin","sequence":"additional","affiliation":[{"name":"7Laboratory of Hematology and Immunology, Aix-en-Provence Pertuis Hospital, Aix-en-Provence, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-9733","authenticated-orcid":false,"given":"Julien","family":"Demagny","sequence":"additional","affiliation":[{"name":"8Laboratory of Hematology, Amiens-Picardie University Hospital, Amiens, France"},{"name":"9H\u00e9matopo\u00ef\u00e8se et Immunologie HEMATIM UR666, Jules Verne University of Picardie, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9307-2852","authenticated-orcid":false,"given":"Fanny","family":"Menard","sequence":"additional","affiliation":[{"name":"10Laboratory of Hematology, Hospital Center of C\u00f4te Basque, Bayonne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-739X","authenticated-orcid":false,"given":"Doroth\u00e9e","family":"Faille","sequence":"additional","affiliation":[{"name":"11Laboratory of Hematology, Bichat University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"12Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S-1144, Optimisation Th\u00e9rapeutique en Neuropharmacologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-8221","authenticated-orcid":false,"given":"Christine","family":"Mouton","sequence":"additional","affiliation":[{"name":"13Laboratory of Hematology, H\u00f4pital Cardiologique du Haut-L\u00e9v\u00eaque University Hospital Center de Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3459-7397","authenticated-orcid":false,"given":"Emmanuel","family":"De Maistre","sequence":"additional","affiliation":[{"name":"14Laboratory of Hematology, Dijon Bourgogne University Hospital, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-0774","authenticated-orcid":false,"given":"Pierre","family":"Fontana","sequence":"additional","affiliation":[{"name":"15Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland"},{"name":"16Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3946-2312","authenticated-orcid":false,"given":"Laetitia","family":"Mauge","sequence":"additional","affiliation":[{"name":"17Hematology Department, Assistance Publique\u2013H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France"},{"name":"18Paris Cit\u00e9 University, INSERM PARCC, UMR-S-970, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-9931","authenticated-orcid":false,"given":"Annabelle","family":"Dupont","sequence":"additional","affiliation":[{"name":"19Hemostasis and Transfusion Department, Lille University, Lille University Hospital, Lille, France"},{"name":"20Pasteur Institute, INSERM Unit 1011, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-242X","authenticated-orcid":false,"given":"Christophe","family":"Nougier","sequence":"additional","affiliation":[{"name":"21Clinical Hemostasis Unit and Laboratory of Hematology, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0878-8818","authenticated-orcid":false,"given":"Nathalie","family":"H\u00e9zard","sequence":"additional","affiliation":[{"name":"22Biog\u00e9nop\u00f4le, Laboratory of Hematology, H\u00f4pital de la Timone, Assistance Publique\u2013H\u00f4pitaux de Marseille, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-6375","authenticated-orcid":false,"given":"Elodie","family":"Boissier","sequence":"additional","affiliation":[{"name":"23Laboratory of Hematology, La\u00ebnnec Hospital, Nantes University Hospital, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-0263","authenticated-orcid":false,"given":"Dominique","family":"Lasne","sequence":"additional","affiliation":[{"name":"24Laboratory of Hematology, Necker University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-5460","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Grand","sequence":"additional","affiliation":[{"name":"25Laboratory of Hematology, Poitiers University Hospital, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-7713","authenticated-orcid":false,"given":"Paul","family":"Billoir","sequence":"additional","affiliation":[{"name":"26Vascular Hemostasis Unit, University Hospital Center of Rouen, Rouen, France"},{"name":"27Universit\u00e9 de Rouen Normandie, INSERM U1096, Endoth\u00e9lium, Valvulopathies et Insuffisance Cardiaque, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-0086","authenticated-orcid":false,"given":"Agathe","family":"Herb","sequence":"additional","affiliation":[{"name":"28Laboratory of Hematology, H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-4732","authenticated-orcid":false,"given":"Corinne","family":"Frere","sequence":"additional","affiliation":[{"name":"29Tenon University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Sorbonne Universit\u00e9, Paris, France"},{"name":"30Sorbonne Universit\u00e9, INSERM UMR-S-1166, Institut Hospitalo-Universitaire ICAN, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2871-166X","authenticated-orcid":false,"given":"Sophie","family":"Voisin","sequence":"additional","affiliation":[{"name":"31Laboratory of Hematology, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7887-2866","authenticated-orcid":false,"given":"Nicolas","family":"Sillamy","sequence":"additional","affiliation":[{"name":"32Laboratory of Hematology, Tours University Hospital, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-3416","authenticated-orcid":false,"given":"Claire","family":"Flaujac","sequence":"additional","affiliation":[{"name":"33Laboratory of Hematology, Versailles Andr\u00e9 Mignot Hospital Center, Le Chesnay-Rocquencourt, Le Chesnay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-6099","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[{"name":"34Universit\u00e9 Catholique de Louvain, CHU UCL Namur, Namur, Belgium"},{"name":"35Namur Thrombosis and Hemostasis Center, Namur Research Institute for LIfe Sciences, Institut de Recherche Exp\u00e9rimentale et Clinique, Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6509-8964","authenticated-orcid":false,"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[{"name":"1Lariboisi\u00e8re University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (Nord), Paris, France"},{"name":"12Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S-1144, Optimisation Th\u00e9rapeutique en Neuropharmacologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-5975","authenticated-orcid":false,"given":"Georges","family":"Jourdi","sequence":"additional","affiliation":[{"name":"1Lariboisi\u00e8re University Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris (Nord), Paris, France"},{"name":"12Universit\u00e9 Paris Cit\u00e9, INSERM UMR-S-1144, Optimisation Th\u00e9rapeutique en Neuropharmacologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"9","key":"2026090811325170800_bib1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCRESAHA.116.306925","article-title":"Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants","volume":"118","author":"Chan","year":"2016","journal-title":"Circ Res"},{"issue":"10264","key":"2026090811325170800_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"2026090811325170800_bib3","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2016.06.003","article-title":"Bleeding with direct oral anticoagulants vs warfarin: clinical experience","volume":"129","author":"Eikelboom","year":"2016","journal-title":"Am J Med"},{"issue":"15","key":"2026090811325170800_bib4","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026090811325170800_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2026090811325170800_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026090811325170800_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/ijms23010093","article-title":"Recent advances in anticoagulant treatment of immune thrombosis: a focus on direct oral anticoagulants in heparin-induced thrombocytopenia and anti-phospholipid syndrome","volume":"23","author":"Carr\u00e9","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026090811325170800_bib8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/medicina57090960","article-title":"The role of direct oral anticoagulants in cancer-associated thrombosis according to the current literature","volume":"57","author":"Nana","year":"2021","journal-title":"Medicina"},{"issue":"7","key":"2026090811325170800_bib9","doi-asserted-by":"crossref","first-page":"EVIDoa2300067","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an on-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"issue":"15","key":"2026090811325170800_bib10","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.3390\/jcm12154984","article-title":"DOACs in the anticoagulation of mechanical valves: a systematic review and future perspectives","volume":"12","author":"Langenaeken","year":"2023","journal-title":"J Clin Med"},{"issue":"13","key":"2026090811325170800_bib11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2026090811325170800_bib12","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026090811325170800_bib13","doi-asserted-by":"crossref","first-page":"51833","DOI":"10.31083\/BJHM51833","article-title":"Stuck between a rock and a hard place: anticoagulation in end-stage kidney disease patients with atrial fibrillation","volume":"87","author":"Wang","year":"2026","journal-title":"Br J Hosp Med (Lond)"},{"key":"2026090811325170800_bib14","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.5114\/amsad\/161172","article-title":"Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy","volume":"8","author":"Patail","year":"2023","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"7","key":"2026090811325170800_bib15","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1111\/jgs.18894","article-title":"The DOAC-FRAIL study, evaluation of direct oral anticoagulant-levels in acutely admitted frail older patients: an exploratory study","volume":"72","author":"de Jong","year":"2024","journal-title":"J Am Geriatr Soc"},{"issue":"13","key":"2026090811325170800_bib16","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"05","key":"2026090811325170800_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1055\/s-0041-1735971","article-title":"The association between factor XI deficiency and the risk of bleeding, cardiovascular, and venous thromboembolic events","volume":"122","author":"Sharman Moser","year":"2022","journal-title":"Thromb Haemost"},{"issue":"11","key":"2026090811325170800_bib18","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"issue":"suppl 1","key":"2026090811325170800_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1538-7836.2011.04311.x","article-title":"Lessons from genome-wide association studies in venous thrombosis","volume":"9","author":"Morange","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026090811325170800_bib20","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/ene.15820","article-title":"Leveraging genetic predictors of factor XI levels to anticipate results from clinical trials","volume":"30","author":"Daghlas","year":"2023","journal-title":"Eur J Neurol"},{"issue":"8","key":"2026090811325170800_bib21","doi-asserted-by":"crossref","first-page":"e019644","DOI":"10.1161\/JAHA.120.019644","article-title":"Genetically proxied inhibition of coagulation factors and risk of cardiovascular disease: a Mendelian randomization study","volume":"10","author":"Yuan","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"02","key":"2026090811325170800_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"10","key":"2026090811325170800_bib23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"2026090811325170800_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"2026090811325170800_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199107183250303","article-title":"Factor XI deficiency in Ashkenazi Jews in Israel","volume":"325","author":"Asakai","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2026090811325170800_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/asheducation-2009.1.97","article-title":"Factor XI deficiency--resolving the enigma?","volume":"2009","author":"Bolton-Maggs","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"2026090811325170800_bib27","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1538-7836.2012.04844.x","article-title":"Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026090811325170800_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"2026090811325170800_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"2026090811325170800_bib30","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"10333","key":"2026090811325170800_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"10357","key":"2026090811325170800_bib32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"2026090811325170800_bib33","doi-asserted-by":"crossref","first-page":"106742","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106742","article-title":"Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention","volume":"31","author":"Sharma","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"16","key":"2026090811325170800_bib34","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"issue":"10","key":"2026090811325170800_bib35","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3324\/haematol.2023.283682","article-title":"Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings","volume":"109","author":"Cohen","year":"2024","journal-title":"haematol"},{"issue":"1","key":"2026090811325170800_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811325170800_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamacardio.2025.0277","article-title":"Asundexian or apixaban in patients with atrial fibrillation according to prior oral anticoagulant use: a subgroup analysis of the OCEANIC-AF randomized clinical trial","volume":"10","author":"Alexander","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"15","key":"2026090811325170800_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"issue":"6","key":"2026090811325170800_bib39","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026090811325170800_bib40","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jtha.2025.05.030","article-title":"Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents","volume":"23","author":"Buckley","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026090811325170800_bib41","doi-asserted-by":"crossref","first-page":"102950","DOI":"10.1016\/j.rpth.2025.102950","article-title":"Impact of asundexian on a panel of coagulation assays","volume":"9","author":"Vassart","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2026090811325170800_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bjh.16776","article-title":"Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis","volume":"191","author":"Baker","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2026090811325170800_bib43","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.jtha.2025.05.032","article-title":"DOAC-Stop reverses the anticoagulant effect of asundexian and milvexian","volume":"23","author":"Fitzpatrick","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2026090811325170800_bib44","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/diagnostics14171991","article-title":"Laboratory evaluation of interferences associated with factor XIa inhibitors asundexian and milvexian in routine coagulation assays","volume":"14","author":"Buckley","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"2026090811325170800_bib45","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1016\/j.jtha.2025.06.016","article-title":"Effect of heparins, direct oral anticoagulants, and factor XII\/factor XI inhibitors on catheter-initiated thrombin generation in platelet-rich plasma: an in vitro study","volume":"23","author":"Hardy","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2026090811325170800_bib46","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1007\/s00277-024-05718-8","article-title":"APTT critical value establishment in four different reagent\/instrument systems based on single factor deficiencies","volume":"103","author":"Huang","year":"2024","journal-title":"Ann Hematol"},{"issue":"15","key":"2026090811325170800_bib47","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026090811325170800_bib48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/17474086.2016.1191944","article-title":"Why factor XI deficiency is a clinical concern","volume":"9","author":"Wheeler","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2026090811325170800_bib49","doi-asserted-by":"crossref","first-page":"102860","DOI":"10.1016\/j.rpth.2025.102860","article-title":"Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis","volume":"9","author":"Godier","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"2026090811325170800_bib50","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jtha.2025.02.025","article-title":"Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"13","key":"2026090811325170800_bib51","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026090811325170800_bib52","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J Med Chem"},{"issue":"10","key":"2026090811325170800_bib53","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026090811325170800_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jth.14667","article-title":"Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH","volume":"18","author":"Cooper","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026090811325170800_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jth.15109","article-title":"Recommendations for clinical laboratory testing for protein S deficiency: communication from the SSC committee plasma coagulation inhibitors of the ISTH","volume":"19","author":"Marlar","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026090811325170800_bib56","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jtha.2025.06.028","article-title":"Effects of milvexian alone or with heparin on catheter-induced clotting and thrombin generation","volume":"23","author":"Yin","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026090811325170800_bib57","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1016\/j.jtha.2025.07.027","article-title":"Laboratory testing of factor XI inhibitors: methodological challenges remain","volume":"23","author":"Hardy","year":"2025","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5762\/2541068\/blooda_adv-2026-020472-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5762\/2541068\/blooda_adv-2026-020472-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:33:02Z","timestamp":1788881582000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5762\/568742\/A-comprehensive-multicenter-study-assessing-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":57,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020472","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,26]]}}}